Emtricitabine/Rilpivirine/Tenofovir Alafenamide (Odefsey)
The Latest
This Week in HIV Research: From PrEP to Treatment, There's Always More to Learn
April 18, 2019: lamivudine/raltegravir for PrEP; feminizing hormone may impact PrEP efficacy; why TAF has a better renal profile than TDF; the role of internet dating in HIV incidence trends.
TAF as Effective as TDF in Cisgender Women, With Fewer Side Effects
A pooled analysis presented at CROI 2019 showed fewer kidney and bone density issues with tenofovir alafenamide in cisgender women than were found with the older formulation.
This Week in HIV Research: Renal Upsides for Tenofovir Alafenamide
E/C/F/TAF viability for dialysis patients; TAF safety following renal damage; mental health needs for American Indians; parenting desires of people with HIV.
Approval of TAF/FTC/RPV, Another Single Pill HIV Treatment Option
The U.S. FDA approval of Odefsey "is a nice advance, especially for those patients at risk for renal and/or bone disease," writes Paul Sax, M.D.
New Single Tablet Regimen Odefsey Approved for Treating HIV Infection
On March 1, 2016, a new single tablet regimen (STR) was approved by the U.S. FDA for treating HIV infection. Called Odefsey, the new once-a-day pill is comprised of three HIV drugs: emtricitabine, rilpivirine and tenofovir alafenamide (TAF).
Odefsey: New HIV Combination Pill Is More Gentle on Bones, Kidneys
The FDA has approved a new once-daily drug regimen for the treatment of HIV. Odefsey, by Gilead Sciences, is composed of emtricitabine, rilpivirine and tenofovir alafenamide.
Switching to Emtricitabine/Tenofovir Alafenamide (F/TAF) Maintains Viral Suppression With Better Bone and Kidney Safety
Switching from treatment regimens containing tenofovir/emtricitabine (Truvada, F/TDF) to regimens containing emtricitabine/tenofovir alafenamide (F/TAF) maintains undetectable viral loads and improves renal and bone safety, according to a CROI 2016 s...